LL-37(17-32)

LL-37 (17-32) (2-10 μM; 72 h) specifically reverses ABCG2-mediated multidrug resistance in MCF-7 FLV1000 cells and ABCG2-transfected HEK293 cells; at a concentration of 10 μM, it reduces the resistance fold of mitoxantrone to 43 and 5.4, respectively, and does not affect the cytotoxicity of non-ABCG2 substrate drugs or the viability of parental cells at effective concentrations^[1].
LL-37 (17-32) (10-40 μM; 1.5 h) inhibits ABCG2-mediated pheophorbide A efflux in MCF-7 FLV1000 cells in a concentration-dependent manner and increases intracellular substrate retention^[1].
LL-37 (17-32) (10-40 μM; 2 h) increases mitoxantrone accumulation in ABCG2-overexpressing MCF-7 FLV1000 cells in a concentration-dependent manner, but exerts no such effect on parental MCF-7 cells^[1].
LL-37 (17-32) (10-40 μM; 55 min) enhances the binding of 5D3 antibody to ABCG2 in MCF-7 FLV1000 cells in a concentration-dependent manner, indicating a direct interaction with this transporter^[1].
LL-37 (17-32) (0.4-50 μM; 45 min) inhibits vanadate-sensitive ABCG2 ATPase activity in crude membranes of ABCG2-expressing High Five insect cells in a concentration-dependent manner^[1].
LL-37 (17-32) (5-20 μM; 24 h) downregulates the expression of ABCG2 protein in MCF-7 FLV1000 cells in a concentration-dependent manner via the lysosomal degradation pathway, without altering ABCG2 mRNA levels^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.